The
reactivity of the multisite (amino)cyclotriphosphazene ligands, [N3P3(NHCy)6] and [N3P3(NHCy)3(NMe2)3], has been explored
in order to obtain silver(I) metallophosphazene complexes. Two series
of cationic silver(I) metallophosphazenes were obtained and characterized:
[N3P3(NHCy)6{AgL}
n
](TfO)
n
[n = 2,
L = PPh3 (2), PPh2Me (4); n = 3, L = PPh3 (3),
PPh2Me (5), TPA (TPA = 1,3,5-triaza-7-phosphaadamantane, 6)] and nongem-trans-[N3P3(NHCy)3(NMe2)3{AgL}
n
](TfO)
n
[n = 2, L = PPh3 (7), PPh2Me (9); n = 3, L = PPh3 (8), PPh2Me (10)]. 5, 7, and 9 have also been characterized
by single-crystal X-ray diffraction, thereby allowing key bonding
information to be obtained. Compounds 2–6, 9, and 10 were screened for in
vitro cytotoxic activity against two tumor human cell lines, MCF7
(breast adenocarcinoma) and HepG2 (hepatocellular carcinoma), and
for antimicrobial activity against five bacterial species including
Gram-positive, Gram-negative, and Mycobacteria strains. Both the IC50 and MIC values revealed excellent biological activity for
these metal complexes, compared with their precursors and cisplatin
and also AgNO3 and silver sulfadiazine, respectively. Both
IC50 and MIC values are among the lowest values found for
any silver derivatives against the cell lines and bacterial strains
used in this work. The structure–activity relationships were
clear. The most cytotoxic and antimicrobial derivatives were those
with the triphenylphosphane and [N3P3(NHCy)6] ligands. A significant improvement in the activity was also
observed upon a rise in the number of silver atoms linked to the phosphazene
ring.